# EDGAR Filing Document

**Accession Number:** 0001858685
**File Stem:** 0001213900-25-067663
**Filing Date:** 2025-7
**Character Count:** 50396
**Document Hash:** 7e622ae0b09f34ebefc572f0e75db5d8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-067663.hdr.sgml**: 20250725

**ACCESSION NUMBER**: 0001213900-25-067663

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20250725

**DATE AS OF CHANGE**: 20250725

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biofrontera Inc.
- **CENTRAL INDEX KEY:** 0001858685
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473765675
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-93395
- **FILM NUMBER:** 251151209

**BUSINESS ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801
- **BUSINESS PHONE:** 781-245-1325

**MAIL ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DEUTSCHE BALATON AKTIENGESELLSCHAFT
- **CENTRAL INDEX KEY:** 0001571071

**ORGANIZATION NAME:**
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** ZIEGELHAUSER LANDSTRABE 1
- **CITY:** HEIDELBERG
- **STATE:** 2M
- **ZIP:** 691924-0
- **BUSINESS PHONE:** 49 6221 64727-0

**MAIL ADDRESS:**
- **STREET 1:** ZIEGELHAUSER LANDSTRABE 1
- **CITY:** HEIDELBERG
- **STATE:** 2M
- **ZIP:** 691924-0

## Ex-1

**Schedule 1**

**Members of Management of the Reporting Entities**

The members of the supervisory board of BFAG are Alexander Link (chairman), Helge Lubenow (deputy Chairman), Hansjörg Plaggemars, Tobias Reich, Karlheinz Schmelig and Heikki Lanckriet. The sole member of the executive board of BFAG is Pilar de la Huerta Martinez.

The members of the management board of DB are Rolf Birkert and Alexander Link and members of the supervisory board of DB are Wilhelm Konrad Thomas Zours, Dr Burkhard Schaefer and Mr. Philip Hornig. The sole member of the management board of VVB is Mr. Zours. The members of the supervisory board of VVB are Philip Hornig, Burkhard Schaefer and Harald Schaefer. The members of the management board of DU are Mr. Zours and Mr. Plaggemars. The members of the supervisory board of DU are Karin Lergenmueller, Philip Hornig, and Burkhard Schaefer.

The following table sets forth the name, present occupation or employment and citizenship of each such person.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Present<br> Business Address** | **Present Occupation** | **Citizenship** |
| **Rolf Birkert** | Ziegelhaeuser Landstrasse 3,<br> 69120 Heidelberg, Germany | Investor; Member of the Management Board of DB<br> Member of the Management Board of Deutsche Balaton Biotech AG;<br> Member of the Management Board of Pflege.Digitalisierung Invest AG<br> Member of the Management Board of Latonba AG<br> Member of the Management Board of Talbona AG;<br> Managing Director of BB19 Unternehmensberatung UG;<br> Managing Director of BB96 Beteiligungen GmbH; | Germany |
| **Alexander Link** | Ziegelhaeuser Landstrasse 3,<br> 69120 Heidelberg, Germany | Investor; Member of the Management Board of DB;<br> Non-Executive Director of 4basebio PLC;<br> Supervisory Board member and chairman of BFAG;<br> Supervisory Board member and chairman of SPK Süddeutsche Privatkapital AG;<br> Supervisory Board member and chairman of SPARTA Invest AG;<br> Member of the Supervisory Board of Epigenomics AG;<br> Member of the Supervisory Board of bioXXmed AG;<br> Member of the Supervisory Board of MISTRAL Media AG;<br> Member of the Supervisory Board of CARUS AG;<br> Member of the Supervisory Board of DIO Deutsche Immobilien Opportunitäten AG;<br> Member of the Supervisory Board of Nestmedic S.A. | Germany |
| **Wilhelm Konrad Thomas Zours** | Ziegelhaeuser Landstrasse 3,<br> 69120 Heidelberg, Germany | Investor; sole Member of the Management Board of VVB; Member of the Management Board of DU;<br> Member of the Supervisory Board and chairman of DB;<br> Member of the Supervisory Board and deputy chairman of Beta Systems Software AG | Germany |
| **Hansjörg Plaggemars** | Ziegelhaeuser Landstrasse 3,<br> 69120 Heidelberg, Germany | Member of the Supervisory Board of BFAG;<br> Member of the Board of 2invest AG;<br> Member of the Management Board of Altech Advanced Materials AG;<br> Member of the Executive Board of Epigenomics AG;<br> Member of the Management Board of DU;<br> Member of the Management Board of Heidelberger Beteiligungsholding AG;<br> Non-executive Director of GeoPacific Resources Ltd;<br> Non-executive Director of 4basebio PLC;<br> Non-executive Director of Wiluna Mining Corporation;<br> Non-executive Director of Altech Batteries Limited;<br> Non-executive Director of Patronus Resources Limited;<br> Member of the Management Board of Strawtec Group AG<br> Liquidator of Alpha Cleantec AG;<br> Managing Director of KiCo Invest GmbH;<br> Managing Director of BALATON Estate Ltd;<br> Managing Director of BALATON Great Lakes Ltd. | USA |
| **Tobias Reich** | Ziegelhaeuser Landstrasse 3,<br> 69120 Heidelberg, Germany | Member of the Supervisory Board of BFAG; Chief Executive Officer and Member of the Board of ConBrio Beteiligungen AG. | Germany |
| **Helge Lubenow** | Hemmelrather Weg 201, D-51377 Leverkusen, Germany | Member of the Supervisory Board of BFAG;<br> Member and chairwoman of the supervisory board of Epigenomics AG;<br> Chief Executive Officer of Epignostix GmbH | Germany |
| **Heikki Lanckriet** | Hemmelrather Weg 201, D-51377 Leverkusen, Germany | Member of the Supervisory Board of BFAG;<br> Chief Executive Officer of 4basebio PLC<br> Member of the Board of Directors of Biofrontera Inc. | Belgium |
| **Mr. Karlheinz Schmelig** | Hemmelrather Weg 201, D-51377 Leverkusen, Germany | Member of the Supervisory Board of BFAG;<br> Managing partner of Creathor Ventures Management GmbH | Germany |
| **Ms. Pilar de la Huerta Martinez** | Hemmelrather Weg 201, D-51377 Leverkusen, Germany | Chief Financial Officer/Managing Director of BFAG;<br> Sole Member of the Executive Board of BFAG;<br> Managing director of Biofrontera Bioscience GmbH;<br> Managing director of Biofrontera PHARMA GmbH;<br> Managing director of Biofrontera Development GmbH;<br> Managing director of Biofrontera Neuroscience GmbH;<br> Director of Biofrontera UK Ltd.<br> Member of the Board of Directors of Vaxdyn S.L.<br> Member of the Board of Directors of Epidisease S.L.<br> Member of the Board of Directors of Creatsens Health<br> Member of the Board of Directors of CELAX Innovation S.L.<br> Member of the Board of Directors Sarcorem S.L. | Spain |
| **Ms. Karin Lergenmueller** | Ziegelhaeuser Landstrasse 3,<br> 69120 Heidelberg, Germany | Member and chairman of the Supervisory Board of DELPHI Unternehmensberatung Aktiengesellschaft;<br> Member and chair(wo)man of the Supervisory Board of Alpha Cleantec AG i. L.;<br> Member of the Supervisory Board of Deutsche Balaton Biotech AG; | Germany |
| **Mr. Philip Hornig** | Ziegelhaeuser Landstrasse 3,<br> 69120 Heidelberg, Germany | Member of the Supervisory Board of DELPHI Unternehmensberatung Aktiengesellschaft and of VV Beteiligungen Aktiengesellschaft;<br> Member of the Supervisory Board of DB;<br> Member and chairman of the Supervisory Board of capFlow AG i.L.;<br> Member of the Supervisory Board of SPK Süddeutsche Privatkapital AG; | Germany |
| **Mr. Burkhard Schaefer** | Ziegelhaeuser Landstrasse 3,<br> 69120 Heidelberg, Germany | Member of the Supervisory Board of DU and VV Beteiligungen Aktiengesellschaft;<br> Member of the Supervisory Board of DB;<br> Member and chairman of the Supervisory Board of Altech Advanced Materials AG;<br> Member and chairman of the Supervisory Board of MISTRAL Media AG;<br> Member of the Supervisory Board of Alpha Cleantec AG i.L.; | Germany |
| **Mr. Harald Schaefer** | Ziegelhaeuser Landstrasse 3,<br> 69120 Heidelberg, Germany | Member and chairman of the Supervisory Board of VV Beteiligungen Aktiengesellschaft;<br> Member and chairman of the Supervisory Board of Rostra AG;<br> supervisory board member and chairman of Strawtec Group AG;<br> Member of the Supervisory Board of SPK Süddeutsche Privatkapital AG | Germany |

---

## Exhibit 99.1

**Exhibit 99.1**

**JOINT FILING AGREEMENT**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

---

| | | |
|:---|:---|:---|
| Date: July 25, 2025 | **<u>BIOFRONTERA AG</u>** | **<u>BIOFRONTERA AG</u>** |
|  | By: | **/s/** Pilar de la Huerta Martinez |
|  | Name: | Pilar de la Huerta Martinez |
|  | Title: | Chief Financial Officer |
|  | **<u>DEUTSCHE BALATON AKTIENGESELLSCHAFT</u>** | **<u>DEUTSCHE BALATON AKTIENGESELLSCHAFT</u>** |
|  | By: | /s/ Alexander Link |
|  | Alexander Link | Alexander Link |
|  | By: | **/**s/ Rolf Birkert |
|  | Rolf Birkert | Rolf Birkert |
|  | **<u>VV BETEILIGUNGEN AKTIENGESELLSCHAFT</u>** | **<u>VV BETEILIGUNGEN AKTIENGESELLSCHAFT</u>** |
|  | By: | **/s/** Wilhelm Konrad Thomas Zours |
|  | Wilhelm Konrad Thomas Zours | Wilhelm Konrad Thomas Zours |
|  | **<u>Delphi Unternehmensberatung<br> Aktiengesellschaft</u>** | **<u>Delphi Unternehmensberatung<br> Aktiengesellschaft</u>** |
|  | By: | **/s/** Wilhelm Konrad Thomas Zours |
|  | Wilhelm Konrad Thomas Zours | Wilhelm Konrad Thomas Zours |
|  | **<u>ALEXANDER LINK</u>** | **<u>ALEXANDER LINK</u>** |
|  | By: | /s/ Alexander Link |
|  | **<u>Wilhelm Konrad Thomas Zours</u>** | **<u>Wilhelm Konrad Thomas Zours</u>** |
|  | By: | **/s/** Wilhelm Konrad Thomas Zours |
|  | **<u>Hansjoerg Plaggemars</u>** | **<u>Hansjoerg Plaggemars</u>** |
|  | By: | **/s/** Hansjoerg Plaggemar |
|  | **<u>Pilar de la Huerta Martinez</u>** | **<u>Pilar de la Huerta Martinez</u>** |
|  | By: | **/s/** Pilar de la Huerta Martinez |

---

## Exhibit 99.4

**Exhibit 99.4**

**POWER OF ATTORNEY**

**KNOW ALL MEN BY THESE PRESENTS**, that the undersigned each hereby constitutes and appoints **Philipp Wiedmann, Dr. Martin Flick** and **Alexander Link**, and each of them separately and singly, his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of the undersigned as an individual or in the undersigned's capacity as an officer, director, board member, or other representative, as applicable, of any corporation, limited liability company or other entity, pursuant to the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, and the Investment Advisers Act of 1940, in each case as amended from time to time, and any and all rules and regulations of the United States Securities and Exchange Commission promulgated thereunder, or pursuant to any U.S. state securities or "blue sky" law, or the rules of any U.S. national securities exchange, registered securities association, or other self-regulatory organization (collectively, "<u>U.S. Securities Laws and Rules</u>"), under seal or otherwise, and to acknowledge and file or furnish the same, with all exhibits thereto, and any other documents in connection therewith, with the United States Securities and Exchange Commission, and with any other entity, when and if such execution, acknowledgment, and filing or furnishing is mandated by the U.S. Securities Laws and Rules, or any of them, as applicable, granting unto said attorney-in-fact the full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, to fulfill the foregoing purposes, to the full extent that the undersigned might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. The above-named attorneys-in-fact and their substitutes shall have no liability to the undersigned or any such corporation, limited liability company or other entity for any liability, cost, or damage incurred by any such attorney-in-fact or his substitutes, and shall be indemnified and held harmless for the same, absent willful misconduct or gross negligence, provided that no such person shall be indemnified for any such liability, cost or damage resulting from any violation of U.S. Securities Laws and Rules by such person.

**IN WITNESS WHEREOF**, this Power of Attorney has been signed as of the 25th day of July, 2025.

---

| |
|:---|
| /s/ Hansjoerg Plaggemars |
| Hansjoerg Plaggemars |
| /s/ Pilar de la Huerta Martinez |
| Pilar de la Huerta Martinez |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**Biofrontera Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**09077D209**

*(CUSIP Number)*

**Dr. Martin Flick**<br>Ziegelhaeuser Landstrasse 3<br>Heidelberg 2M 69120<br>496221649240

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/30/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **09077D209** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Biofrontera AG** | Name of reporting person<br>**Biofrontera AG** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**400000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**400000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**400000.00** | Aggregate amount beneficially owned by each reporting person<br>**400000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.23%** | Percent of class represented by amount in Row (11)<br>**4.23%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **09077D209** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Deutsche Balaton Aktiengesellschaft** | Name of reporting person<br>**Deutsche Balaton Aktiengesellschaft** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**58884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**400000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**58884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**400000.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.86%** | Percent of class represented by amount in Row (11)<br>**4.86%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **09077D209** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**VV Beteiligungen Aktiengesellschaft** | Name of reporting person<br>**VV Beteiligungen Aktiengesellschaft** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**458884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**458884.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.86%** | Percent of class represented by amount in Row (11)<br>**4.86%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **09077D209** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Delphi Unternehmensberatung Aktiengesellschaft** | Name of reporting person<br>**Delphi Unternehmensberatung Aktiengesellschaft** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**458884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**458884.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.86%** | Percent of class represented by amount in Row (11)<br>**4.86%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **09077D209** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Wilhelm Konrad Thomas Zours** | Name of reporting person<br>**Wilhelm Konrad Thomas Zours** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**458884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**458884.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.86%** | Percent of class represented by amount in Row (11)<br>**4.86%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **09077D209** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Alexander Link** | Name of reporting person<br>**Alexander Link** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**458884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**458884.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.86%** | Percent of class represented by amount in Row (11)<br>**4.86%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **09077D209** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Hansjoerg Plaggemars** | Name of reporting person<br>**Hansjoerg Plaggemars** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**458884.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**458884.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | Aggregate amount beneficially owned by each reporting person<br>**458884.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.86%** | Percent of class represented by amount in Row (11)<br>**4.86%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

| **CUSIP No.** | **09077D209** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Pilar de la Huerta Martinez** | Name of reporting person<br>**Pilar de la Huerta Martinez** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**U3** | Citizenship or place of organization<br>**U3** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**400000.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**400000.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**400000.00** | Aggregate amount beneficially owned by each reporting person<br>**400000.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.23%** | Percent of class represented by amount in Row (11)<br>**4.23%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
Biofrontera Inc.

**(c) Address of Issuer's Principal Executive Offices:**
120 Presidential Way,, Suite 330, Woburn, MA, 01801

**Item 4. Purpose of Transaction**

Explanatory Note: There is no agreement among the Reporting Persons, written or oral, with respect to the acquisition, ownership, voting or disposition of any securities of the Issuer, and the Reporting Persons disclaim the existence of any group among them within the meaning of Section 13(d)(3) of the Act or the rules and regulations of the Securities and Exchange Commission ("SEC") promulgated thereunder. All percentages herein are based on 9,446,197 shares of common stock outstanding as reported by the Issuer as of May 13, 2025, in its Quarterly Report on Form 10-Q filed on May 15, 2025.

The information set forth in Item 3 of this Amendment No. 3 to Schedule 13D is hereby incorporated by reference into this Item 4.

Prior to November 2, 2021, the Issuer was a wholly owned subsidiary of BFAG. On November 2, 2021, the Issuer consummated its initial public offering ("IPO") of 3,600,000 units, each consisting of (i) one share of common stock of the Issuer and (ii) one warrant entitling the holder to purchase one share of the Issuer's common stock at an exercise price of $5.00 per share, and such equity securities were registered under Section 12(b) of the Act. Immediately following the IPO, BFAG owned 8,000,000 shares of common stock, or approximately 69.0% of the Issuer's then outstanding shares of common stock. According to the Issuer's publicly-available filings with the SEC, following the IPO, the Issuer entered into numerous transactions involving the issuance of Issuer equity securities and/or rights, resulting in substantial dilution to BFAG. In addition, according to such filings, effective as of 11:59 pm, July 3, 2023, the Issuer effected a 1-for-20 reverse stock split of its then outstanding shares of common stock (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the 8,000,000 shares of Issuer common stock held by BFAG immediately following the IPO were converted into 400,000 shares of Issuer common stock. Other than the 3,019 shares of Series D Preferred Stock issued to BFAG pursuant to the Agreement, BFAG has not acquired any equity securities of the Issuer since the IPO. BFAG has not sold any equity securities of the Issuer since the IPO.

DB purchased the shares of common stock reported on this Amendment No. 3 to Schedule 13D for investment purposes. In addition, DB sought to offset in part the economic dilution resulting to BFAG (and, indirectly, to BFAG's shareholders) as a result of the Issuer's repeated issuances of common stock and warrants, as described in the Issuer's publicly-available filings with the SEC. As a result of the Reverse Stock Split, the 1,177,680 shares of common stock of the Issuer purchased by DB were converted into 58,884 shares of common stock.

Subject to market conditions, DB currently intends to acquire additional voting securities of the Issuer, or instruments convertible into voting securities of the Issuer, as DB may from time to time deem desirable for investment purposes. Any such acquisitions may be effected through open market purchases, block trades, privately-negotiated transactions, subscriptions made pursuant to rights offerings by the Issuer, or otherwise (including the exercise of any options or other securities exercisable for, or convertible into, any such securities of the Issuer).

Subject to market conditions, DB may also dispose of voting securities of the Issuer from time to time, as DB deems desirable. Any such dispositions may be effected through open market sales, block trades, privately-negotiated transactions, or otherwise.

On December 13, 2021, DB filed an action against BFAG with the local court of Cologne, Germany. DB argues that the listing of the common stock by the Issuer on NASDAQ and the issuance of common stock to third parties as part of the IPO required approval at BFAG's general meeting. The local court of Cologne ruled that BFAG's board resolutions regarding the IPO of the Issuer are void because BFAG had to obtain its general meeting's approval. However, the former board members and members of the supervisory board of BFAG joined the litigation and lodged an appeal against such ruling to the Higher Regional Court of Cologne, Germany. The Higher Regional Court of Cologne, Germany rejected the litigation but permitted the appeal to the Federal Supreme Court. DB has not yet taken a decision on whether it will go to the Federal Supreme Court in this particular case.

The Reporting Individuals, DU and VVB currently do not intend to acquire securities of the Issuer directly.

BFAG, except for its contingent right to convert its shares of Series D Preferred Stock into shares of the Issuer's common stock, which it may do at any time upon the Issuer's receipt of the Stockholder Approval, does not currently intend to acquire additional securities of the Issuer directly. Additionally, pursuant to the Agreement, effective as of June 30, 2025 and for three years following such date, for so long as BFAG holds any shares of Series D Preferred Stock, or any shares of common stock issued upon the conversion of shares of Series D Preferred Stock, BFAG shall have the right to appoint one member of the Issuer's board of directors if the board of directors consists of up to seven members, and two members if the board of directors consists of eight or more members.

Except as set forth above, the Reporting Persons have no current plans or proposals with respect to (i) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; (ii) any extraordinary corporate transaction, such as a merger, reorganization, or liquidation, involving the Issuer or any of its subsidiaries, (iii) a sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries, (iv) any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; (v) any material change in the present capitalization or dividend policy of the Issuer; (vi) any other material change in the Issuer's business or corporate structure, (vii) changes to the Issuer's organizational documents or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (viii) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (ix) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to section 12(g)(4) of the Act; or (x) any action similar to any of the foregoing.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The beneficial ownership of each of the Reporting Persons in the shares of the Issuer's common stock to which this statement relates is as follows:

BFAG holds 400,000 shares of the Issuer's common stock, which constitutes 4.23% of the beneficial ownership of the shares of the Issuer's common stock.

DB beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG. DB, directly and indirectly through certain of its subsidiaries, holds 42.6% of the outstanding voting shares in BFAG and, as of June 12, 2024, consolidates BFAG for financial reporting purposes. Mr. Link, a management board member of DB, is a member and serves as chairman of the supervisory board of BFAG. As chairman, Mr. Link is entitled to the casting vote in the event that any vote of the supervisory board would otherwise result in a tie. In addition, two other supervisory board members of BFAG, Mr. Hansjorg Plaggemars and Mr. Tobias Reich, serve as management board members of certain subsidiaries of DB. As a result of such stock ownership and relationships, DB may be deemed to have shared voting power and/or shared dispositive power over the shares of the Issuer held by BFAG. However, DB disclaims beneficial ownership of the shares of the Issuer held by BFAG.

VVB beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG, which may be deemed to be beneficially owned by DB. VVB owns a majority interest in DB, and therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. However, pursuant to a non-domination agreement between VVB and DB (the "Non-Domination Agreement"), VVB has agreed that it cannot exercise voting control (through voting more than 45%, directly or indirectly, of the shares) over DB. Accordingly, VVB disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB (whether directly or through BFAG) in excess of 45% of the voting power thereof.

DU beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG, which may be deemed to be beneficially owned by DB. DU owns a majority interest in VVB, which owns a majority interest in DB, and therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. However, based on the Non-Domination Agreement between VVB and DB, DU disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB in excess of 45% of the voting power thereof. Note that, in addition to the voting shares in BFAG held by DB and its subsidiaries, DU directly holds a 19.6% voting interest in BFAG. Accordingly, disregarding the effect of the Non-Domination Agreement, DU, VVB and DB collectively hold 62.2% of the outstanding voting stock of BFAG and therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer held by BFAG. DU disclaims beneficial ownership of the shares of the Issuer beneficially owned by BFAG.

Wilhelm Konrad Thomas Zours beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG, which may be deemed to be beneficially owned by DB. Mr. Zours owns a majority interest in DU and is the sole member of the management board of VVB and - together with Mr. Plaggemars - board member of DU, and in such roles therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. Based on the Non-Domination Agreement, Mr. Zours disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB in excess of 45% of the voting power thereof. Mr. Zours further disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB and/or BFAG, except to the extent of his pecuniary interest therein. Mr. Zours does not own any shares of the Issuer in his individual capacity.

Alexander Link beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG. Mr. Link is a member of the management board of DB and in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. Mr. Link is also a member and chairman of the supervisory board of BFAG and in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by BFAG. Mr. Link disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB and/or BFAG. Mr. Link does not own any shares of the Issuer in his individual capacity.

Hansjoerg Plaggemars beneficially owns 458,884 shares of the Issuer's common stock, which constitutes 4.86% of the aggregate beneficial ownership of such class. The 458,884 shares beneficially owned consists of the 58,884 shares held directly by DB and the 400,000 shares held by BFAG, which may be deemed to be beneficially owned by DB. DU owns a majority interest in VVB, which owns a majority interest in DB, and therefore may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. Mr. Plaggemars is a member of the management board of DU, and in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by DB. Mr. Plaggemars is also a member of the supervisory board of BFAG, in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by BFAG. Mr. Plaggemars disclaims beneficial ownership of the shares of the Issuer beneficially owned by DB and/or BFAG. Mr. Plaggemars does not own any shares of the Issuer in his individual capacity.

Pilar de la Huerta Martinez beneficially owns 400,000 shares of the Issuer's common stock, which constitutes 4.23% of the aggregate beneficial ownership of such class. The 400,000 shares beneficially owned consists of the 400,000 shares held by BFAG. Mrs. Huerta Martinez is the sole member of the management board of BFAG, and in such role may be deemed to have shared voting and dispositive power over the shares of the Issuer beneficially owned by BFAG. Mrs. Huerta Martinez disclaims beneficial ownership of the shares of the Issuer beneficially owned by BFAG. Mrs. Huerta Martinez does not own any shares of the Issuer in her individual capacity.

For the reasons set forth above, the Reporting Persons may be deemed to constitute a group under Section 13(d)(3) of the Act, but each disclaim existence of any such group.

All percentages relating to the Issuer's common stock set forth in this Amendment No. 3 to Schedule 13D are based on 9,446,197 shares of common stock outstanding as reported by the Issuer as of May 13, 2025, in its Quarterly Report on Form 10-Q filed on May 15, 2025.

**(b)**
(i) BFAG has sole power to vote or direct the vote of, and sole power to dispose or direct the disposition of 400,000 shares of the Issuer's common stock. BFAG does not have shared power to vote or direct the vote of, or shared power to dispose or direct the disposition of, any shares of the Issuer's common stock.

(ii) DB has sole power to vote or direct the vote of, and sole power to dispose or direct the disposition of 58,884 shares of the Issuer's common stock. DB has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 400,000 shares.

(iii) VVB does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, VVB has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(iv) DU does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, DU has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(v) Mr. Zours does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, Mr. Zours has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(vi) Mr. Link does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, Mr. Link has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(vii) Mr. Plaggemars does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, Mr. Plaggemars has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 458,884 shares of the Issuer's common stock.

(viii) Mrs. Huerta Martinez does not have sole power to vote or direct the vote of, or sole power to dispose or to direct the disposition of any shares of the Issuer's common stock. Based on the factors set forth in Item 5(a), above, Mrs. Huerta Martinez has shared power to vote or direct the vote of, and shared power to dispose or direct the disposition of, 400,000 shares of the Issuer's common stock.

**(c)**
During the 60 day period preceding the date of this filing, the Reporting Persons have not purchased or sold any shares of common stock of the Issuer. However, as described above, during the 60 day period preceding the date of this filing, BFAG has acquired 3,019 shares of the Issuer's Series D Preferred Stock.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

None.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Biofrontera AG

**Signature:** /s/ Pilar de la Huerta Martinez

**Name/Title:** Pilar de la Huerta Martinez, Chief Financial Officer

**Date:** 07/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Deutsche Balaton Aktiengesellschaft

**Signature:** /s/ Rolf Birkert

**Name/Title:** Rolf Birkert

**Date:** 07/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** VV Beteiligungen Aktiengesellschaft

**Signature:** /s/ Wilhelm Konrad Thomas Zours

**Name/Title:** Wilhelm Konrad Thomas Zours

**Date:** 07/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Delphi Unternehmensberatung Aktiengesellschaft

**Signature:** /s/ Wilhelm Konrad Thomas Zours

**Name/Title:** Wilhelm Konrad Thomas Zours

**Date:** 07/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Wilhelm Konrad Thomas Zours

**Signature:** /s/ Wilhelm Konrad Thomas Zours

**Name/Title:** Wilhelm Konrad Thomas Zours

**Date:** 07/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Alexander Link

**Signature:** /s/ Alexander Link

**Name/Title:** Alexander Link

**Date:** 07/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Hansjoerg Plaggemars

**Signature:** /s/ Hansjoerg Plaggemar

**Name/Title:** Hansjoerg Plaggemars

**Date:** 07/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Pilar de la Huerta Martinez

**Signature:** /s/ Pilar de la Huerta Martinez

**Name/Title:** Pilar de la Huerta Martinez

**Date:** 07/25/2025